Cohort of Elderly Patients with T2D. Comparing the Risk of Hypoglycaemia in DPP4-Inhibitors (iDPP4) with Conventional Oral Antidiabetic Drugs as Add-On Therapy to Metformin. FRESH-PEF73265-en Sylvie DEJAGER Cohort of Elderly Patients with T2D. Comparing the Risk of Hypoglycaemia in DPP4-Inhibitors (iDPP4) with Conventional Oral Antidiabetic Drugs as Add-On Therapy to Metformin. HYPOCRAS FRESH-PEF73265-en 73265 FRESH-PEF73265 Isabelle BOURDEL-MARCHASSON Alfred PENFORNIS Sylvie DEJAGER CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX NOVARTIS PHARMA SAS CHU BESANCON (CHU) Epidemiology France Portal (PEF) NOVARTIS PHARMA SAS null Isabelle;BOURDEL-MARCHASSON Alfred;PENFORNIS Sylvie;DEJAGER type 2 diabetes elderly subject DPP4 inhibitors oral antidiabetic drugs hypoglycaemia Endocrinology Type 2 diabetes mellitus Healthcare system determinants: Use of care Behavioral determinants: Eating habits Healthcare system determinants Behavioral determinants HYPOCRAS aims to compare hypoglycaemic risk in dipeptidyl peptidase-4 inhibitors (iDPP4s) with other oral antidiabetic drugs (OAD) along with metaformin in the real-life treatment of elderly patients with type 2 diabetes (T2D). null France Individuals Patients population Male Female Aged (65 to 79 years) Aged, 80 and over (80 years and more) Patients eligible for the study were men and women of 65 years of age or over with T2D and HbA1c: ≥6.5% after a course of at least 3 months of metformin alone at a stable, maximum tolerated daily dose, requiring the prescription of a second OAD. Patients who had at least two follow-up visits planned over the next 6 months (± 1 month, 3 months, 6 months ± 1 month). Clinical data Health care consumption and services Other Through independent healthcare practitioners [1000-10000[ individuals Other Observational Study Observational Study Cohort study 1,317 Unknown Restricted access Contact the principal investigator Access on specific project only